Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UX-DA001 in Idiopathic Parkinson's Disease
NCT06778265Phase 1Active, not recruiting
- Sponsor
- UniXell Biotechnology
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UX-DA001 in Parkinson's disease (PD), sponsored by UniXell Biotechnology. Primary endpoints: Incidence and severity of adverse events associated with surgery and/or investigational product at 4 weeks and Incidence and severity of AEs/serious adverse events at 2 years. Started Mar 2025; status: active, not recruiting.
02
Drugs
UX-DA001
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06778265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06778265.